Abstract Reconstructive surgery with a flap makes the definition of postoperative radiotherapy volumes challenging. It may also result in errors in automatic segmentation atlases of organ-at-risk and nodal volumes. Automating flap segmentation process could assist clinicians in planning radiotherapy and enable characterization of flap evolution over time and after radiotherapy. Flaps vary significantly in shape, volumes and associated artefacts.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jean Bourhis
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 tria
Get full text access Log in, subscribe or purchase for full access. References 1. Pignon, JP ∙ le Maître, A ∙ Maillard, E ∙ et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiother Oncol. 2009; 92:4-14 2. Cooper, JS ∙ Pajak, TF ∙ Forastiere, AA ∙ et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck N Engl J Med. 2004; 350:1937-1944 3.
Xevinapant + chemoradiotherapy in LA SCCHN: extended follow-up of a phase II clinical trial
Head and neck cancer is one of the most common types of cancer worldwide. Over 90% of all head and neck cancers are squamous cell carcinoma of the head and neck (SCCHN) and most patients (around 60%) are diagnosed with the locally advanced (LA) form of the disease. The current standard of care (SoC) for these patients is either surgery followed by chemoradiotherapy (CRT) or definitive CRT (focused on cure or long-term control) for the 50% of patients that do not undergo surgery (unresected).
How Stereotactic Radiotherapy Changed the Landscape in Cancer Care
Open AccessEditorial by Rémy Kinj * and Jean Bourhis Service of Radiation Oncology, Department of Oncology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland * Author to whom correspondence should be addressed.
AsiaNet - View Release
CHUV, CERN and THERYQ join forces for a world first in cancer radiotherapy The Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, the European Laboratory for Particle Physics (CERN) and THERYQ (ALCEN Group) have signed an agreement for the world-first development of a revolutionary FLASH radiotherapy device that will use very high energy electron (VHEE) radiation to treat cancers resistant to conventional treatments.
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC
Jonathan D Schoenfeld and colleagues 1 Schoenfeld JD Giobbie-Hurder A Ranasinghe S et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol.
Avelumab and cetuximab as a therapeutic combination: an overview of scientific rationale and current clinical trials in cancer
Highlights • Avelumab and cetuximab have complementary mechanisms of action. • This combination may result in potential synergistic antitumor effects. • Studies investigating this combination will help inform future treatment strategies. Abstract Treatment outcomes have improved with the advent of immune checkpoint inhibitors and small molecule inhibitors. However, many patients do not respond with single agents.
An imbalance in competing mortality favouring Debio 1143 - Authors' reply
We would like to thank Kaveh Zakeri and colleagues for their Correspondence. Reliability of, and confidence in, disease progression data is dependent on the objective criteria used to define disease progression and tumour response and on the frequency of assessments. Missing tumour assessments can potentially lead to overestimation or underestimation of treatment differences. One way to minimise this bias in our Article 1 Sun X-S Tao Y Le Tourneau C et al.
An imbalance in competing mortality favouring Debio 1143 - Authors' reply
We would like to thank Kaveh Zakeri and colleagues for their Correspondence. Reliability of, and confidence in, disease progression data is dependent on the objective criteria used to define disease progression and tumour response and on the frequency of assessments. Missing tumour assessments can potentially lead to overestimation or underestimation of treatment differences.
High Z nanoparticles and radiotherapy: a critical view
1 Bonvalot S Rutkowski PL Thariat J et al. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial. Lancet Oncol. 2019; 20: 1148-1159 for their study on the use of NBTXR3 in combination with radiotherapy in patients with locally advanced soft-tissue sarcoma.
Clinical translation of FLASH radiotherapy: Why and how?
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 FLASH-RT is more efficient at protecting normal tissues than Amifostine. Amifostine (4 mM; Sigma) was added to the zebrafish embryos water 1 h before irradiation. Irradiation was performed 4 hours post-fertilization (hpf).
Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncolog
According to ICRU definition, the CTV includes the GTV plus a volume of normal tissue at risk for microscopic tumour infiltration with a probability of occurrence considered relevant for therapy [19x[19]Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy IMRT. International Commission on Radiation Units and Measurements (ICRU), report 83; 2010.Google ScholarSee all References][19].
Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
The true value of altered fractionation in head and neck cancer
Reply to N.F. Saba and S.J. Wong
In response to our recent report,1 Saba and Wong2 make a number of important observations regarding the potential role for dual epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) –targeted therapy as part of combined chemoradiotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jean
Contact Jean, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack